JP Morgan Chase
FHTX icon

JP Morgan Chase’s Foghorn Therapeutics FHTX Stock Holding History

JP Morgan Chase’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82.6K Buy
18,685
+1,466
+9% +$8.05K ﹤0.01% 5934
2025
Q4 		$93K Buy
17,219
+773
+5% +$3.5K ﹤0.01% 5927
2025
Q3 		$80.4K Sell
16,446
-2,277
-12% -$12.1K ﹤0.01% 6027
2025
Q2 		$88K Buy
18,723
+2,597
+16% +$10.9K ﹤0.01% 5660
2025
Q1 		$58.9K Sell
16,126
-40,405
-71% -$184K ﹤0.01% 5819
2024
Q4 		$267K Buy
56,531
+45,565
+416% +$332K ﹤0.01% 5353
2024
Q3 		$102K Sell
10,966
-87
-0.8% -$630 ﹤0.01% 5692
2024
Q2 		$63.6K Sell
11,053
-2,985
-21% -$17.8K ﹤0.01% 5754
2024
Q1 		$94.2K Buy
14,038
+862
+7% +$4.79K ﹤0.01% 5699
2023
Q4 		$85K Sell
13,176
-7,841
-37% -$33.8K ﹤0.01% 5807
2023
Q3 		$105K Buy
21,017
+3,921
+23% +$30.2K ﹤0.01% 5442
2023
Q2 		$120K Buy
17,096
+1,596
+10% +$11.2K ﹤0.01% 5378
2023
Q1 		$96K Buy
15,500
+4,125
+36% +$27K ﹤0.01% 5445
2022
Q4 		$73K Buy
11,375
+395
+4% +$2.98K ﹤0.01% 5478
2022
Q3 		$94K Buy
10,980
+236
+2% +$3.04K ﹤0.01% 5311
2022
Q2 		$146K Buy
10,744
+1,570
+17% +$20.3K ﹤0.01% 5230
2022
Q1 		$140K Buy
9,174
+1,664
+22% +$22.8K ﹤0.01% 5363
2021
Q4 		$172K Sell
7,510
-4,192
-36% -$60.3K ﹤0.01% 5434
2021
Q3 		$163K Sell
11,702
-14,533
-55% -$161K ﹤0.01% 5333
2021
Q2 		$280K Buy
26,235
+6,224
+31% +$67.8K ﹤0.01% 5061
2021
Q1 		$264K Buy
20,011
+372
+2% +$6.1K ﹤0.01% 5032
2020
Q4 		$399K Buy
+19,639
New +$376K ﹤0.01% 4500

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

JP Morgan Chase's FHTX Position: Q1 2026 in Review

JP Morgan Chase increased its Foghorn Therapeutics (FHTX) stake by 8.5% in Q1 2026, buying an estimated $8.05K and bringing the position to 18,685 shares worth $82.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5934.

JP Morgan Chase first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $399K in Q4 2020. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • JP Morgan Chase held 18,685 shares of Foghorn Therapeutics worth $82.6K as of Q1 2026.
  • JP Morgan Chase bought 1,466 Foghorn Therapeutics shares in Q1 2026, an estimated $8.05K.
  • Foghorn Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5934 holding.
  • JP Morgan Chase first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Foghorn Therapeutics position peaked at $399K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.